Proteinase 3 and prognosis of patients with acute myocardial infarction
- PMID: 20942801
- PMCID: PMC2999885
- DOI: 10.1042/CS20100366
Proteinase 3 and prognosis of patients with acute myocardial infarction
Abstract
A multimarker approach may be useful for risk stratification in AMI (acute myocardial infarction) patients, particularly utilizing pathways that are pathophysiologically distinct. Our aim was to assess the prognostic value of PR3 (proteinase 3) in patients post-AMI. We compared the prognostic value of PR3, an inflammatory marker, with an established marker NT-proBNP (N-terminal pro-B-type natriuretic peptide) post-AMI. We recruited 900 consecutive post-AMI patients (700 men; age, 64.6±12.4 years) in a prospective study with follow-up over 347 (0-764) days. Plasma PR3 was significantly higher in patients who died [666.2 (226.8-4035.5) ng/ml; P<0.001] or were readmitted with heart failure [598 (231.6-1803.9) ng/ml, P<0.004] compared with event-free survivors [486.9 (29.3-3118.2) ng/ml]. Using Cox modelling, log10 PR3 [HR (hazard ratio), 3.80] and log10 NT-proBNP (HR, 2.51) were significant independent predictors of death or heart failure. When patients were stratified by plasma NT-proBNP (median, 1023 pmol/l), PR3 gave additional predictive value for death or heart failure, in both the patients in whom NT-proBNP level was above the median (log rank for trend, 12.54; P<0.0004) and those with NT-proBNP level below the median (log rank for trend, 3.83; P<0.05). Neither marker predicted recurrent AMI. In conclusion, this is the first report showing a potential role for the serine protease PR3 in determining mortality and incidence of heart failure following AMI, independent of established conventional risk factors. PR3 may represent a clinically useful marker of prognosis after an AMI as part of a multimarker strategy.
Figures


Similar articles
-
Plasma N-terminal B-Type natriuretic peptide as an indicator of long-term survival after acute myocardial infarction: comparison with plasma midregional pro-atrial natriuretic peptide: the LAMP (Leicester Acute Myocardial Infarction Peptide) study.J Am Coll Cardiol. 2008 May 13;51(19):1857-64. doi: 10.1016/j.jacc.2008.01.041. J Am Coll Cardiol. 2008. PMID: 18466800
-
Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction.Eur Heart J. 2009 May;30(9):1057-65. doi: 10.1093/eurheartj/ehn600. Epub 2009 Jan 23. Eur Heart J. 2009. PMID: 19168526
-
Matrix metalloproteinase-2 predicts mortality in patients with acute coronary syndrome.Clin Sci (Lond). 2009 Nov 9;118(4):249-57. doi: 10.1042/CS20090226. Clin Sci (Lond). 2009. PMID: 19583569
-
C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study.Circulation. 2007 Apr 24;115(16):2103-10. doi: 10.1161/CIRCULATIONAHA.106.685503. Epub 2007 Apr 9. Circulation. 2007. PMID: 17420344 Clinical Trial.
-
Serum uric acid as an independent and incremental prognostic marker in addition to N-terminal pro-B-type natriuretic peptide in patients with acute myocardial infarction.Circ J. 2011;75(6):1440-7. doi: 10.1253/circj.cj-10-0952. Epub 2011 Apr 16. Circ J. 2011. PMID: 21498911
Cited by
-
Sodium tanshinone IIA sulfonate prevents the adverse left ventricular remodelling: Focus on polymorphonuclear neutrophil-derived granule components.J Cell Mol Med. 2019 Jul;23(7):4592-4600. doi: 10.1111/jcmm.14306. Epub 2019 May 8. J Cell Mol Med. 2019. PMID: 31066232 Free PMC article. Clinical Trial.
-
Role of various proteases in cardiac remodeling and progression of heart failure.Heart Fail Rev. 2012 May;17(3):395-409. doi: 10.1007/s10741-011-9269-8. Heart Fail Rev. 2012. PMID: 21739365 Review.
-
Neutrophil-Enriched Biomarkers and Long-Term Prognosis in Acute Coronary Syndrome: a Systematic Review and Meta-analysis.J Cardiovasc Transl Res. 2024 Apr;17(2):426-447. doi: 10.1007/s12265-023-10425-2. Epub 2023 Aug 18. J Cardiovasc Transl Res. 2024. PMID: 37594719 Free PMC article.
-
Temporal cardiac remodeling post-myocardial infarction: dynamics and prognostic implications in personalized medicine.Heart Fail Rev. 2016 Jan;21(1):25-47. doi: 10.1007/s10741-015-9513-8. Heart Fail Rev. 2016. PMID: 26498937
-
PR3 levels are impaired in plasma and PBMCs from Arabs with cardiovascular diseases.PLoS One. 2020 Jan 14;15(1):e0227606. doi: 10.1371/journal.pone.0227606. eCollection 2020. PLoS One. 2020. PMID: 31935243 Free PMC article.
References
-
- Libby P., Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111:3481–3488. - PubMed
-
- Friedman G. D., Klatsky A. L., Siegelaub A. B. The leukocyte count as a predictor of myocardial infarction. N. Engl. J. Med. 1974;290:1275–1278. - PubMed
-
- Naruko T., Ueda M., Haze K., van der Wal A. C., van der Loos C. M., Itoh A., Komatsu R., Ikura Y., Ogami M., Shimada Y., et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation. 2002;106:2894–2900. - PubMed
-
- Buffon A., Biasucci L. M., Liuzzo G., D'Onofrio G., Crea F., Maseri A. Widespread coronary inflammation in unstable angina. N. Engl. J. Med. 2002;347:5–12. - PubMed
-
- Fu X., Kassim S. Y., Parks W. C., Heinecke J. W. Hypochlorous acid oxygenates the cysteine switch domain of pro-matrilysin (MMP-7). A mechanism for matrix metalloproteinase activation and atherosclerotic plaque rupture by myeloperoxidase. J. Biol. Chem. 2001;276:41279–41287. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials